|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2007-4-5
|
|
pubmed:abstractText |
Several previous clinical trials have shown that malignant pleural mesothelioma is responsive to antifolates. The dihydrofolate reductase inhibitor, pralatrexate, has a favorable toxicity profile, primarily limited to stomatitis, and has demonstrated activity in patients with non-small cell lung cancer. In mesothelioma cell lines and xenografts, pralatrexate demonstrated significant antitumor activity.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1556-1380
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
2
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
317-20
|
|
pubmed:dateRevised |
2008-5-6
|
|
pubmed:meshHeading |
pubmed-meshheading:17409804-Aged,
pubmed-meshheading:17409804-Aged, 80 and over,
pubmed-meshheading:17409804-Aminopterin,
pubmed-meshheading:17409804-Confidence Intervals,
pubmed-meshheading:17409804-Dose-Response Relationship, Drug,
pubmed-meshheading:17409804-Drug Administration Schedule,
pubmed-meshheading:17409804-Female,
pubmed-meshheading:17409804-Humans,
pubmed-meshheading:17409804-Male,
pubmed-meshheading:17409804-Maximum Tolerated Dose,
pubmed-meshheading:17409804-Mesothelioma,
pubmed-meshheading:17409804-Middle Aged,
pubmed-meshheading:17409804-Neoplasm Staging,
pubmed-meshheading:17409804-Palliative Care,
pubmed-meshheading:17409804-Pleural Neoplasms,
pubmed-meshheading:17409804-Probability,
pubmed-meshheading:17409804-Prognosis,
pubmed-meshheading:17409804-Risk Assessment,
pubmed-meshheading:17409804-Survival Analysis,
pubmed-meshheading:17409804-Terminally Ill
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma.
|
|
pubmed:affiliation |
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA. krugl@mskcc.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Research Support, N.I.H., Extramural
|
